

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Fortaz 6 g/Vial Injection (DIN 02212234) manufactured by GlaxoSmithKline, Ceftazidime 6 g/Vial Injection (DIN 00886963) manufactured by Fresenius Kabi Canada will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of February 11, 2016, all claims for Ceftazidime 6 g/Vial Injection (DIN 00886963) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics, and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortages of Apo-Propafenone 150 mg Tablet (DIN 02243324) manufactured by Apotex Inc. and Rythmol 150 mg Tablet (DIN 00603708) manufactured by Abbott Laboratories Limited, Mylan-Propafenone 150 mg Tablet (DIN 02245372) manufactured by Mylan Pharmaceuticals ULC was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Abbott Laboratories Limited has advised Alberta Blue Cross that the shortage of Rythmol 150 mg Tablet (DIN 00603708) has been resolved.

As a result, Mylan-Propafenone 150 mg Tablet (DIN 02245372) will no longer be considered as a temporary benefit for the *ADBL* after **March 22, 2016**.

Due to the shortages of Apo-Brimonidine 0.2% Ophthalmic Solution (DIN 02260077), manufactured by Apotex Inc., Sandoz Brimonidine 0.2% Ophthalmic Solution (DIN 02305429), manufactured by Sandoz Canada Inc., and Alphagan 0.2% Ophthalmic Solution (DIN 02236876), manufactured by Allergan Inc., Brimonidine P 0.15% Ophthalmic Solution (DIN 02301334), manufactured by AA Pharma Inc. was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Apotex Inc. has advised Alberta Blue Cross that the shortage of Apo-Brimonidine 0.2% Ophthalmic Solution (DIN 02260077) has been resolved.

As a result, Brimonidine P 0.15% Ophthalmic Solution (DIN 02301334) will no longer be considered as a temporary benefit for the *ADBL* after **March 23, 2016**.

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. that the shortage of Apo-Atenidone 100/25 mg Tablet (DIN 02248764) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 22, 2016**.

ATENOLOL / CHLORTHALIDONE

100 MG / 25 MG ORAL TABLET

00002248764	APO-ATENIDONE	APX	\$ 0.5236
00002302926	TEVA-ATENOLTHALIDONE	TEV	\$ 0.5498
00002049988	TENORETIC 100/25	AZC	\$ 1.1099

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free)

FAX 780-498-8406 (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>

